SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
October 15, 2001
----------------
(Date of earliest event reported)
ATRIX LABORATORIES, INC.
------------------------
(Exact name of Registrant as specified in its charter)
Delaware 0-18231 84-1043826
------------------------ ----------------------- -------------------
(State or Other Jurisdiction (Commission File No.) (IRS Employer
of Incorporation) Identification No.)
2579 Midpoint Drive, Fort Collins, Colorado 80525
-------------------------------------------------
(Address of principal executive offices, including zip code)
(970) 482-5868
--------------
(Registrant's telephone number, including area code)
Item 5. Other Events.
On October 15, 2001, Atrix Laboratories, Inc. (the "Company") entered
into a Collaboration, License and Supply Agreement with Fujisawa Healthcare,
Inc., a subsidiary of Fujisawa Pharmaceutical Company, Ltd. ("Fujisawa"), under
which the Company granted Fujisawa the exclusive North American marketing and
distribution rights for the Company's proprietary dermatological product,
Atrisone(TM) dapsone topical gel. Under the terms of the agreement, the Company
will receive up to $25 million in licensing fees, research and development
support, and milestone payments. The Company will also receive royalties based
on North American sales of the products. As part of the Agreement, the Company
will manufacture the product for Fujisawa and receive a manufacturing margin.
The text of the press release announcing the transaction is attached
hereto as Exhibit 99.1.
Item 7. Exhibits.
99.1 Press Release dated as of October 17, 2001
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ATRIX LABORATORIES, INC.
By: /s/ BRIAN G. RICHMOND
-------------------------------
Brian G. Richmond
Chief Financial Officer
Date: October 17, 2001
EXHIBIT INDEX
EXHIBIT DESCRIPTION
------- -----------
99.1 Press Release dated as of October 17, 2001